成都康弘药业集团股份有限公司 2017 年半年度报告全文 () was and 成都康弘药业集团股份有限公司 2017 年半年度报告 2017年08月 l 成都康弘药业集团股份有限公司 2017年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和 连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能存在销售价格下降、药品研发、募投项目实施、人才缺乏等风险, 有关风险因素内容已在本报告中第四节"经营情况讨论与分析"第十部分"公司 面临的风险和应对措施"部分予以描述。敬请广大投资者注意投资风险。 公司计划不派发现金红利,不送红股,不以公积金转增股本。 2 成都康弘药业集团股份有限公司 2017年半年度报告全文 | | | | 2017 半年度报告 . | | --- | | 第一节 重要提示、释义 | | 第二节 公司简介和主要财务指 ...

成都康弘药业集团股份有限公司 2017 年第一季度报告正文 证券代码：002773 证券简称：康弘药业 公告编号：2017-027 成都康弘药业集团股份有限公司 2017 年第一季度报告正文 1 成都康弘药业集团股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证季度报告中财务报表的真实、准确、完整。 成都康弘药业集团股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 2 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 642,039,416.94 | 523,601,977.96 | 22.62 ...

成都康弘药业集团股份有限公司 2016 年年度报告全文 成都康弘药业集团股份有限公司 2016 年年度报告 2017-010 2017 年 04 月 1 成都康弘药业集团股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能存在销售价格下降、药品研发、募投项目实施、人才缺乏等风险， 有关风险因素内容已在本报告中第四节 "经营情况讨论与分析"第九部分"公司 未来发展的展望"部分予以描述。敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以现有总股本 674,954,060 股为基数，向全体股东每 10 股派发现金红利 1.50 元（含税），送红股 0 股（含 税），不以公积金转增股本。 2 | 目录 | | --- | | 第一节 | 重要提 ...

成都康弘药业集团股份有限公司 2016 年第三季度报告全文 成都康弘药业集团股份有限公司 2016 年第三季度报告 2016 年 10 月 1 成都康弘药业集团股份有限公司 2016 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证季度报告中财务报表的真实、准确、完整。 2 成都康弘药业集团股份有限公司 2016 年第三季度报告全文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,627,813,372.13 | | 2,901,190,093.95 | 25.05% | | ...

成都康弘药业集团股份有限公司 2016 年半年度报告全文 成都康弘药业集团股份有限公司 2016 年半年度报告 2016 年 08 月 1 成都康弘药业集团股份有限公司 2016 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证本半年度报告中财务报告的真实、准确、完整。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者 的实质性承诺，敬请投资者注意投资风险。 2 | 目录 | | --- | | 2016 | 半年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 5 | | 第二节 | 公司简介 7 | | 第三节 | 会计数据和财务指标摘要 9 | | 第四节 | 董事会报告 20 | | 第五节 | 重要事项 26 | ...

成都康弘药业集团股份有限公司 2016 年第一季度报告正文 证券代码：002773 证券简称：康弘药业 公告编号：2016-020 成都康弘药业集团股份有限公司 2016 年第一季度报告正文 1 成都康弘药业集团股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证季度报告中财务报表的真实、准确、完整。 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -41,711.32 | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 一标准定额或定量享受的政府补助除外） | 2,504,419.83 | | | 除上述各项之外的其他营业外收入和支出 | -3,130,934.70 | | | 减 ...

成都康弘药业集团股份有限公司 2015 年年度报告全文 成都康弘药业集团股份有限公司 2015 年年度报告 2016-015 2016 年 04 月 1 成都康弘药业集团股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能存在销售价格下降、药品研发、募投项目实施、人才缺乏等风险， 有关风险因素内容已在本报告中第四节"管理层讨论与分析"第九部分"公司未 来发展的展望"部分予以描述。敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 449,856,040 为基数，向 全体股东每 10 股派发现金红利 2 元（含税），送红股 0 股（含税），以资本公积 金向全体股东每 10 股转增 5 股。 2 | 目录 | | --- | | 第一节 重 ...

Financial Performance - Net profit attributable to shareholders rose by 43.97% to CNY 121,067,292.40 for the reporting period[7] - Operating revenue grew by 35.11% to CNY 579,734,508.45 for the reporting period[7] - Basic earnings per share increased by 29.26% to CNY 0.2717 for the reporting period[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 47.25% to CNY 119,311,040.98 for the reporting period[7] - Operating revenue increased by 30.22% year-over-year, driven by the rapid market expansion of the new drug "Kangbai Xip" and stable growth in the Sinochem pharmaceutical business[16] - The estimated net profit attributable to shareholders for 2015 is projected to be between ¥328.18 million and ¥410.22 million, representing a growth of 20.00% to 50.00% compared to ¥273.48 million in 2014[23] Asset and Cash Flow - Total assets increased by 42.13% to CNY 2,758,529,865.38 compared to the end of the previous year[7] - The net cash flow from operating activities surged by 463.03% to CNY 150,371,297.34 year-to-date[7] - Cash and cash equivalents increased by 35.39% compared to the beginning of the year, mainly due to the issuance of new shares[15] - Cash and cash equivalents net increased by 195.08% year-over-year, primarily due to cash inflow from the issuance of new shares[16] - Accounts receivable grew by 175.86% year-to-date, attributed to increased sales and a slowdown in collection efforts[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,854[11] - The largest shareholder, Chengdu Kanghong Technology Industry (Group) Co., Ltd., held 33.61% of the shares[11] - The company reported no significant changes in shareholder structure or any repurchase transactions during the reporting period[12] Expenditures and Liabilities - Development expenditures rose by 32.75% year-to-date, reflecting increased investment in development activities[15] - Long-term receivables decreased by 100.00% year-to-date, as the final payment for the equity transfer of American Saijin was recovered[15] - Short-term borrowings decreased by 100.00% year-to-date, due to the repayment of bank short-term loans by the parent company[15] - Financial expenses decreased by 47.83% year-over-year, attributed to increased interest income from bank deposits and foreign exchange gains[16] Other Financial Activities - The company reported no securities investments during the reporting period[24] - The company did not hold shares in other listed companies during the reporting period[25] - The continuous deepening of specialized academic promotion and communication has led to a steady growth in sales performance, contributing to the positive profit outlook[23]

Financial Performance - The company's operating revenue for the reporting period was ¥891,048,413.32, representing a 27.23% increase compared to ¥700,350,639.32 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was ¥128,026,274.39, up 48.34% from ¥86,303,952.91 year-on-year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥124,234,088.75, reflecting a 59.09% increase from ¥78,092,643.11 in the previous year[17]. - The net cash flow from operating activities was ¥32,772,695.29, a significant improvement of 142.12% compared to a negative cash flow of ¥77,813,553.89 in the same period last year[17]. - Basic earnings per share increased to ¥0.3201, up 48.33% from ¥0.2158 in the previous year[17]. - The diluted earnings per share also stood at ¥0.3201, marking a 48.33% increase year-on-year[17]. - The weighted average return on net assets was 7.83%, an increase of 1.69% from 6.14% in the previous year[17]. - The gross profit margin for the pharmaceutical manufacturing sector was 88.66%, with a slight increase of 0.14% compared to the previous year[32]. - The company achieved a return of 12.8 million from a floating income investment of 3,000 million at a rate of 4.1%[45]. - The company reported a total profit of CNY 153,093,335.54, which is a 44.5% increase from CNY 105,959,232.20 in the previous year[133]. Research and Development - The company's R&D investment amounted to ¥37,791,149.23, reflecting a 10.64% increase compared to the previous year[27]. - The company is in the R&D phase for several new products, including KH110 for Alzheimer's disease and KH903 for colorectal cancer, indicating a focus on innovation[28]. - The company has 12 major products in production and 10 major products in research, focusing on high-incidence diseases with a lack of effective treatment options[35]. - The company aims to enhance its core competitiveness through continuous innovation and strategic layout, particularly in ophthalmology, central nervous system, and digestive system fields[36]. - Chengdu Kanghong is investing 200 million CNY in R&D for new drug development, focusing on oncology and autoimmune diseases[46]. - Chengdu Kanghong is investing 1.4 billion CNY in research and development for new technologies aimed at enhancing product efficacy[49]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces in China by the end of 2015[47]. - The company has outlined a strategic goal to achieve a 15% growth in sales by the end of 2015 through market expansion and product diversification[49]. - Chengdu Kanghong aims to increase its international sales by 30% in 2016, targeting markets in Southeast Asia and Europe[47]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market share[47]. - The company plans to continue expanding its market presence and invest in new product development[146]. Financial Management and Investments - The total amount of funds raised by Chengdu Kanghong Pharmaceutical Group Co., Ltd. was RMB 621,072,000, with a net amount of RMB 576,247,732.49 after deducting related expenses[58]. - The total amount of entrusted financial management funds was RMB 216,805 million, generating a total income of RMB 751.37 million during the reporting period[51]. - The company has diversified its investment portfolio with both fixed and floating income products to optimize returns[44]. - Future investment strategies will continue to emphasize stable returns through fixed income products while exploring opportunities in floating income investments[45]. - The company has committed to timely disclosure of any shareholding changes and has fulfilled its commitments to minority shareholders[99]. Shareholder and Governance Information - The company has established a commitment to adjust the issuance price in case of any capital increase or dividend distribution events[97]. - The governance structure of the company complies with relevant laws and regulations, ensuring proper operation of the shareholders' meeting, board of directors, and supervisory board[75]. - The company’s shareholder structure includes 42.59% held by domestic legal entities and 47.18% held by domestic individuals[106]. - The company has not undergone any changes in controlling shareholders or actual controllers during the reporting period[112]. - The company has not engaged in any external investments or held shares in financial enterprises during the reporting period[39][40][41][42]. Compliance and Regulatory Matters - The financial report was approved by the board of directors on August 26, 2015[163]. - The company’s fundraising activities were approved by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[58]. - The company has maintained continuous profitability over the past three years, justifying the preparation of financial statements on a going concern basis[166]. - The company has not reported any changes in the use of raised funds or any surplus from fundraising projects[62]. - There were no major litigation or arbitration matters during the reporting period[76].